Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;5(2):112-117.
doi: 10.2174/157339609788185686.

RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY

Latania Y Booker  1 , Titilope A Ishola, Kanika A Bowen, Dai H Chung
Affiliations

RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY

Latania Y Booker et al. Curr Pediatr Rev. 2009 May.

Abstract

Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of pediatric cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.

Keywords: Neuroblastoma; antibody-mediated therapy; cell-mediated therapy; cytokine-mediated therapy; immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential Targets for Neuroblastoma Immunotherapy
See this image and copyright information in PMC

References

    1. Society AC. Cancer Facts & Figures 2008. American Cancer Society. 2008
    1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186–95. - PubMed
    1. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia. 2006;8:833–42. - PMC - PubMed
    1. Brodeur GM. Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002;24:608–9. - PubMed
    1. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003;4:472–80. - PubMed

LinkOut - more resources